Basic View | Expanded View
 Showing 1-8 of 8 Articles
Viewpoint  FREE
David Orentlicher, MD, JD; Thaddeus Mason Pope, JD, PhD; Ben A. Rich, JD, PhD
While once widely rejected as a health care option, physician aid in dying is receiving increased recognition as a response to the suffering of patients at the end of life. With aid in dying, a physician writes a prescription for life-ending medication for an eligible patient. Following the recommendation of ...
Viewpoint  FREE
Farzad Mostashari, MD, MPH; Darshak Sanghavi, MD; Mark McClellan, MD, PhD
Even though most adult primary care physicians may not realize it, they each can be seen as a chief executive officer (CEO) in charge of approximately $10 million of annual revenue. Consider that a typical primary care physician has approximately 2000 patients, each of whom annually accounts for about $5000 ...
Medical News & Perspectives  FREE
M. J. Friedrich
A decade of disappointing clinical trial results for Alzheimer disease (AD)-modifying therapies in people suggests that treatment should be targeted at earlier stages in the disease—even before overt symptoms arise.
Viewpoint  FREE
David K. Jones, MSPH, MA; Phillip M. Singer, MHSA; John Z. Ayanian, MD, MPP
It has long been anticipated that 2014 would be the year in which most major elements of the Patient Protection and Affordable Care Act of 2010 (ACA) would be implemented.1 Yet even after surviving legislative, judicial, and electoral challenges, what the law actually will accomplish is uncertain. A major reason ...
Topics: medicaid
Viewpoint  FREE
Sachin H. Jain, MD, MBA; Michael Rosenblatt, MD; Jon Duke, MD, MS
Academic-industry research collaborations have long been a source of controversy in medicine. Advocates suggest that collaborations can focus academic researchers on important clinical and translational research problems and provide them with financial and capability-enhancing technical resources.1 Critics maintain that industry engagement distracts from, or distorts, the teaching and research missions ...
Research Letter  FREE
Masahiro Natsuaki, MD; Ken Kozuma, MD; Takeshi Morimoto, MD; Hiroki Shiomi, MD; Takeshi Kimura, MD
Recent network meta-analyses have raised concerns about the safety of biodegradable polymer drug-eluting stents (BP-DES) compared with durable polymer everolimus-eluting stents (DP-EES).1- 3 The NOBORI Biolimus-Eluting vs XIENCE/PROMUS Everolimus-Eluting Stent Trial (NEXT) is a 98-center, randomized, open-label, noninferiority trial evaluating the efficacy and safety of biodegradable polymer biolimus-eluting stents (BP-BES) ...
Viewpoint  FREE
Adam C. Powell, PhD; Adam B. Landman, MD; David W. Bates, MD
mHealth apps are mobile device applications intended to improve health outcomes, deliver health care services, or enable health research.1 The number of apps has increased substantially, and more than 40 000 health, fitness, and medical apps currently are available on the market.2 Because apps can be used to inexpensively promote ...
Viewpoint  FREE
Anthony S. Fauci, MD; Hilary D. Marston, MD, MPH
The emergence of multidrug-resistant bacteria and the rapid global spread of carbapenem-resistant Enterobacteriaceae (CRE) have recently captured public attention, and some have asked whether the ongoing public health and scientific “war” against drug-resistant microbes, particularly bacteria, can ever be won. In fact, the challenge of antimicrobial resistance is an enduring ...

Sign In

Register for a FREE personal account

and access these and other features:

Register Now

Want to Subscribe?

Learn More about subscription options.

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)